Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Doxazosin + valsartan** is a combination of two antihypertensive agents: doxazosin, an alpha-1 adrenergic receptor antagonist, and valsartan, an angiotensin II receptor blocker (ARB). Doxazosin works by blocking alpha-1 adrenergic receptors, resulting in vasodilation of veins and arteries, thereby lowering blood pressure and relaxing smooth muscles in the bladder neck and prostate[5][7]. Valsartan blocks the angiotensin II type 1 receptor, inhibiting the effects of angiotensin II, which normally causes vasoconstriction and increased aldosterone secretion[1]. This combination can be used as add-on therapy for patients whose hypertension is inadequately controlled by valsartan alone, resulting in further reduction of blood pressure[4]. No unique brand name formulation with this exact combination appears to be marketed, but clinical studies have evaluated its use in combination therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on doxazosin + valsartan.